Search Results - "Huang, XianGao"
-
1
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Published in Blood (14-03-2019)“…Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment…”
Get full text
Journal Article -
2
Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance
Published in Nature communications (29-03-2023)“…Telomere length maintenance is essential for cellular immortalization and tumorigenesis. 5% − 10% of human cancers rely on a recombination-based mechanism…”
Get full text
Journal Article -
3
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function
Published in The FASEB journal (01-12-2015)“…ABSTRACT The immunomodulatory drug (IMiD) thalidomide and its structural analogs lenalidomide and pomalidomide are highly effective in treating clinical…”
Get full text
Journal Article -
4
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas
Published in The Journal of clinical investigation (15-12-2022)“…Targeting lineage-defined transcriptional dependencies has emerged as an effective therapeutic strategy in cancer treatment. Through screening for molecular…”
Get full text
Journal Article -
5
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma
Published in Leukemia & lymphoma (15-10-2019)“…In mantle cell lymphoma (MCL), cyclin D1 combines with CDK4/6 to phosphorylate Rb, releasing a break on the G1 to S phase cell cycle. Palbociclib is a…”
Get full text
Journal Article -
6
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4
Published in Blood (02-08-2012)“…Dysregulation of cyclin-dependent kinase 4 (CDK4) and CDK6 by gain of function or loss of inhibition is common in human cancer, including multiple myeloma, but…”
Get full text
Journal Article -
7
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model
Published in Cancer research (Chicago, Ill.) (15-07-2008)“…Multiple myeloma (MM) remains incurable partly because no effective cell cycle-based therapy has been available to both control tumor cell proliferation and…”
Get full text
Journal Article -
8
MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin
Published in Clinical cancer research (01-07-2011)“…The type I Melanoma Antigen GEnes (MAGEs) are commonly expressed in cancers, fueling speculation that they may be therapeutic targets with oncogenic potential…”
Get full text
Journal Article -
9
Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function
Published in Frontiers in cell and developmental biology (17-12-2020)“…Cereblon (CRBN), a substrate receptor of cullin 4-RING E3 ligase (CRL4), mediates the ubiquitination and degradation of constitutive substrates and…”
Get full text
Journal Article -
10
Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors
Published in Blood (17-02-2011)“…Inhibition of Cdk4/Cdk6 by p18INK4c (p18) is pivotal for generation of noncycling immunoglobulin (Ig)-secreting plasma cells (PCs). In the absence of p18,…”
Get full text
Journal Article -
11
Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide
Published in The Journal of pharmacology and experimental therapeutics (01-12-2021)“…Proteasome inhibitors and immunomodulatory drugs (IMiDs) are two major types of drugs for the treatment of multiple myeloma. Although different combination…”
Get full text
Journal Article -
12
Blind reconnaissance of the pseudo-random sequence in DS/SS signal with negative SNR
Published in Science China. Information sciences (01-06-2007)“…This paper introduces a new theory and algorithm that can be used in blind detection of the carrier wave signal and the pseudo-random sequence of the direct…”
Get full text
Journal Article -
13
Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy
Published in Hematology/oncology clinics of North America (01-10-2020)“…Cell cycle dysregulation caused by aberrant cyclin D1 and CDK4 expression is a major determinant for proliferation of cancer cells in mantle cell lymphoma…”
Get full text
Journal Article -
14
Cell Cycle Dysregulation in Mantle Cell Lymphoma
Published in Hematology/oncology clinics of North America (01-10-2020)“…Cell cycle dysregulation caused by aberrant cyclin D1 and CDK4 expression is a major determinant for proliferation of cancer cells in mantle cell lymphoma…”
Get full text
Journal Article -
15
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma
Published in Cancer discovery (01-09-2014)“…Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is…”
Get more information
Journal Article -
16
Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy
Published in Blood (15-11-2022)Get full text
Journal Article -
17
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1
Published in Proceedings of the National Academy of Sciences - PNAS (21-12-2004)“…Cell-cycle entry is critical for homeostatic control in physiologic response of higher organisms but is not well understood. The antibody response begins with…”
Get full text
Journal Article -
18
Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition
Published in Blood (13-11-2019)“…Lenalidomide (Len) and Pomalidomide (Pom) are immunomodulatory drugs (IMiDs) used for the treatment of multiple myeloma (MM) and have efficacy in other…”
Get full text
Journal Article -
19
Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma
Published in Blood (02-11-2023)“…Drug resistance remains a formidable challenge in mantle cell lymphoma (MCL). Cell cycle dysregulation driven by aberrant Cyclin D1 and CDK4 expression is a…”
Get full text
Journal Article -
20
Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution
Published in Blood (23-11-2021)“…Combined inhibition of BTK with ibrutinib and BCL2 with venetoclax is one of the most promising therapies for B cell malignancies, especially mantle cell…”
Get full text
Journal Article